Potential Serious Risk to Public Health: How It Is Assessed

Introduction

The expression potential serious risk to public health has a specific regulatory meaning in the European Union medicines framework. It is particularly important during mutual recognition procedures (MRPs) and decentralised procedures (DCPs), where a Concerned Member State (CMS) may be unable to approve the assessment report, the summary of product characteristics, the labelling or the package leaflet on these grounds.

The threshold is important because Article 29 of Directive 2001/83/EC provides an escalation mechanism when such a disagreement cannot be resolved among the Member States. It is therefore not simply another way of describing a difficult scientific question, an incomplete dossier or a disagreement between assessors.

The distinction matters in practice. A regulatory team should be able to explain why a concern is merely an unresolved scientific issue, why it may represent a potential serious risk to public health, and what evidence supports that conclusion.

This article explains the concept and the assessment logic without treating the threshold as a numerical scoring system. The applicable legislation, Commission guidance and procedure-specific documents remain the controlling sources for an individual procedure.

1. The Legal Context

Article 29 of Directive 2001/83/EC establishes the mechanism for a Member State that cannot approve the assessment report, SmPC, labelling or package leaflet on grounds of a potential serious risk to public health.

The provision operates within the MRP/DCP framework. A CMS raises the concern and provides a detailed explanation of its position. The issue is then considered through the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), with the objective of reaching agreement.

If the Member States cannot reach agreement within the applicable period, Article 29(4) provides for referral to the European Medicines Agency for the subsequent Union procedure.

The legal sequence is therefore:

MRP / DCP
   ↓
CMS identifies a qualifying concern
   ↓
Detailed statement of reasons
   ↓
CMDh coordination
   ↓
Agreement → procedure proceeds
   │
   └── No agreement → Article 29(4) referral

The potential serious risk to public health concept is consequently both a scientific and a legal threshold.

2. It Is Not a General Scientific-Disagreement Threshold

A CMS and RMS can disagree without creating an Article 29 procedure.

Regulatory procedures routinely involve differences in interpretation, requests for additional information, alternative analyses and discussion of proposed wording. These matters are normally addressed through questions, responses and scientific discussion.

Article 29 is different. The CMS must be unable to approve the relevant regulatory position on the grounds of a potential serious risk to public health.

This means that the following statements are not, by themselves, sufficient:

• "The RMS assessment is not convincing."
• "More data would be useful."
• "There is uncertainty in the clinical evidence."
• "The benefit-risk balance requires further discussion."

Such issues may become relevant to a qualifying concern, but the regulatory record needs to establish the connection between the scientific issue and the potential serious risk to public health.

3. The Commission Guideline

The European Commission issued a guideline specifically concerning the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC.

The guideline is important because the phrase should not be interpreted according to an individual company's internal definition. It provides the regulatory framework for determining when the exceptional Article 29 mechanism may be invoked.

For a live procedure, the current version of the applicable legal and procedural framework should always be checked. Historical guidance can be useful for understanding how the concept developed, but it should not automatically be treated as the current procedural rule.

4. What Is Being Protected?

The threshold is concerned with public health, rather than simply the existence of an individual adverse event or an isolated scientific uncertainty.

Public-health relevance can be influenced by factors such as:

• the seriousness of the possible outcome;
• the magnitude or plausibility of the risk;
• the population potentially exposed;
• the characteristics of the affected population;
• the likelihood and consequences of the harm;
• the quality and consistency of the evidence;
• and the possible effect on the overall benefit-risk balance.

These factors should not be converted into an artificial checklist in which a fixed number of criteria automatically produces an Article 29 concern. The assessment is contextual and must be grounded in the applicable regulatory framework.

5. Safety Is Not the Only Possible Subject

A common misconception is that potential serious risk to public health means a pharmacovigilance issue.

Safety concerns are an important example, but Article 29 disagreements can concern other aspects of the regulatory assessment. The legislation refers to inability to approve the assessment report or relevant product information on the grounds of the potential serious risk to public health.

Depending on the circumstances, the underlying issue may therefore involve safety, efficacy, quality or the proposed product information.

The origin of the procedure is critical. A safety issue arising as an unresolved MRP/DCP disagreement under Article 29 should not automatically be reclassified as a pharmacovigilance referral merely because the scientific subject is safety.

6. Start With the Regulatory Question

The most reliable way to assess a potential serious risk is to define the actual regulatory question before analysing the evidence.

For example:

Can the proposed regulatory position be accepted without creating a potential serious risk to public health?

The question should then be broken into observable components:

1. What is the disputed regulatory conclusion?
2. What scientific evidence supports that conclusion?
3. What evidence supports the CMS concern?
4. What harm could occur if the concern is valid?
5. Which patients or populations could be affected?
6. How credible is the causal or mechanistic explanation?
7. How large or clinically important could the risk be?
8. Does the concern materially affect the benefit-risk balance or the acceptability of the proposed product information?
9. Can the concern be resolved through additional evidence, clarification or an appropriate regulatory measure?

This structure prevents the assessment from starting with a conclusion and searching retrospectively for supporting evidence.

7. Assess the Evidence, Not Just the Signal

A signal may initiate investigation, but a signal is not automatically a potential serious risk to public health.

Evidence should be characterised according to its source and limitations. Relevant evidence may include:

• clinical trials;
• epidemiological studies;
• spontaneous reports and case series;
• literature;
• non-clinical studies;
• pharmacological or mechanistic evidence;
• data concerning related medicinal products;
• exposure estimates;
• and the background incidence of the event in the relevant population.

The assessment should consider the totality of evidence rather than treating one data source as determinative without considering its limitations.

For example, several spontaneous reports may justify a safety investigation but still provide insufficient evidence to establish a causal relationship. Conversely, a small number of highly unusual and serious cases may be highly informative when combined with strong biological plausibility and a distinctive clinical pattern.

8. Consider Alternative Explanations

A serious event does not necessarily indicate a medicinal-product risk.

The assessment should consider alternative explanations such as:

• underlying disease;
• comorbidities;
• concomitant medicines;
• age and other demographic factors;
• exposure to other risk factors;
• background incidence;
• ascertainment or reporting bias;
• confounding;
• and methodological limitations of the available studies.

This is particularly important where the alleged risk is common in the population or strongly associated with the underlying indication.

The regulatory question is not simply whether an event occurred after exposure. It is whether the evidence supports a credible concern that the medicinal product could create a serious public-health risk in the circumstances under consideration.

9. Assess Clinical Seriousness and Consequences

The seriousness of the possible outcome is an important component of the assessment, but seriousness alone is insufficient.

A severe outcome that is biologically implausible and unsupported by credible evidence should not automatically be classified as a potential serious risk to public health.

Conversely, a credible concern involving a rare but catastrophic outcome may warrant serious regulatory consideration even when the available evidence is limited.

The assessment should therefore distinguish at least three questions:

These questions interact rather than functioning as independent numerical scores.

10. Consider Population Exposure

Public-health significance cannot be assessed without considering who may be exposed.

A concern affecting a narrowly defined population may have different public-health implications from a similar concern affecting a medicine used extensively across the EU.

Relevant considerations can include:

• expected patient population;
• duration of exposure;
• frequency of use;
• age distribution;
• use in vulnerable populations;
• geographical distribution;
• and the expected magnitude of exposure after authorisation.

Exposure does not determine the threshold by itself. It provides context for understanding the potential consequences of the concern.

11. Consider the Benefit-Risk Balance

The potential serious risk to public health should be considered in the context of the medicine's benefits.

A credible safety concern may have a different regulatory significance depending on the seriousness of the disease, the availability of alternatives, the magnitude of the therapeutic benefit and whether the risk can be appropriately managed.

This does not mean that a major therapeutic benefit can simply cancel a serious risk. Rather, the overall regulatory assessment needs to determine whether the proposed authorisation and product information remain acceptable in light of the evidence.

Where the concern can be addressed through an appropriate change to product information or another regulatory measure, that possibility should also be considered within the applicable procedure.

12. The Importance of Product Information

Article 29 expressly encompasses disagreement concerning the SmPC, labelling and package leaflet.

A potential serious risk may therefore arise because the proposed product information does not adequately communicate a clinically important risk, contraindication, warning, precaution, adverse reaction or other relevant information.

The assessment should identify the precise information gap and explain its public-health significance.

For example, it is more informative to state that a proposed warning does not adequately address a credible serious risk in an exposed population than simply to state that the SmPC is inadequate.

13. Document the Reasoning Chain

A strong assessment should allow an independent reviewer to reconstruct the reasoning.

A useful structure is:

Evidence
  ↓
Scientific interpretation
  ↓
Potential harm
  ↓
Affected population / exposure
  ↓
Clinical and public-health significance
  ↓
Benefit-risk implications
  ↓
Regulatory conclusion

Each transition should be supported by evidence or an explicitly identified scientific judgement.

This is particularly important because Article 29(1) requires the CMS to provide a detailed exposition of the reasons for its position.

14. What Happens During CMDh Coordination?

Once a qualifying disagreement has been raised, CMDh provides the forum in which the Member States attempt to reach agreement.

The objective is not simply to vote on which authority is correct. The participants examine the scientific and regulatory basis of the disagreement and consider whether the issue can be resolved.

The applicant must be given an opportunity to make its views known orally or in writing.

Possible routes to resolution can include:

• additional evidence or clarification;
• agreement on scientific interpretation;
• revision of product information;
• additional regulatory commitments where appropriate;
• or another agreed regulatory solution within the applicable framework.

If agreement is reached, the Article 29 escalation does not proceed to the Union-level referral.

15. What Happens When Agreement Cannot Be Reached?

If the Member States cannot reach agreement within the applicable period, Article 29(4) provides for referral to the Agency for the procedure under the subsequent provisions of the Directive.

At that point, the unresolved disagreement becomes the subject of a Union-level assessment by CHMP.

The referral documentation should preserve the logic of the original disagreement. The Union-level assessment should be able to identify what was disputed, why it was considered a potential serious risk to public health and what evidence supported the respective positions.

16. Article 29 Is Not Proof That the Medicine Is Unsafe

A formal Article 29 disagreement represents a regulatory concern, not a final scientific conclusion.

The statement:

"An Article 29 referral means the medicine is unsafe."

is therefore incorrect.

The correct interpretation is that a Member State considered that the relevant regulatory position could not be approved because of a potential serious risk to public health, the disagreement could not be resolved through the applicable coordination process, and the matter consequently required further regulatory assessment.

The eventual Union-level assessment may confirm the concern, modify the regulatory position, resolve the concern through appropriate measures, or reach another outcome permitted by the applicable framework.

17. Common Interpretive Errors

Several errors recur when Article 29 disagreements are discussed.

Treating every disagreement as Article 29

Scientific disagreement is normal. Article 29 is an exceptional statutory mechanism with a specific trigger.

Treating uncertainty as the threshold

Uncertainty may be part of the evidence assessment, but uncertainty alone does not establish a potential serious risk to public health.

Treating a safety signal as a confirmed risk

A signal requires evaluation. It does not automatically establish causality or public-health significance.

Ignoring exposure

The possible consequence of a concern depends partly on the population exposed and the likely use of the medicine.

Ignoring alternative explanations

Background disease, concomitant medicines and confounding can materially alter the interpretation of an apparent association.

Treating the process as a PRAC referral

An Article 29 procedure can involve safety, but its legal origin is an unresolved MRP/DCP disagreement. The procedure should not be relabelled solely according to the scientific subject matter.

18. Practical Assessment Checklist

When reviewing a potential serious risk to public health concern, ask:

1. What exact regulatory decision is being disputed?
2. What is the potential harm?
3. What evidence supports an association with the medicinal product?
4. How strong and consistent is that evidence?
5. What alternative explanations exist?
6. How serious is the potential outcome?
7. Which population could be affected?
8. What is the expected exposure?
9. What is the potential public-health impact?
10. How does the concern affect the benefit-risk balance?
11. Can the concern be addressed through product information or another regulatory measure?
12. Has the reasoning been documented in sufficient detail for independent review?
13. Does the concern actually meet the regulatory concept of potential serious risk to public health under the applicable framework?

The final question is deliberately last. The assessment should establish the factual and scientific basis before assigning the legal/regulatory consequence.

19. QPPV and Pharmacovigilance Considerations

For the QPPV and pharmacovigilance organisation, an Article 29 disagreement involving safety can have important consequences even though Article 29 itself is not a pharmacovigilance referral procedure.

The organisation should establish:

• what safety concern is under discussion;
• whether the concern is already tracked through signal management;
• whether it affects the safety specification or RMP;
• whether new evidence should trigger additional safety evaluation;
• whether product-information changes are being considered;
• and whether the regulatory conclusion creates downstream PV obligations.

The QPPV should avoid treating the Article 29 process and the company's internal signal-management process as interchangeable. They are related but serve different purposes.

20. Inspection Considerations

An inspection-ready organisation should be able to demonstrate how a serious regulatory concern was identified, evaluated and governed.

Relevant records may include:

• the original CMS objection;
• scientific evidence reviewed;
• internal safety assessments;
• regulatory strategy and decision records;
• applicant responses;
• CMDh communications;
• product-information proposals;
• relevant signal-management records;
• RMP assessments where applicable;
• and the final regulatory outcome.

The objective is traceability. A later reviewer should be able to understand what was known at each stage, what judgement was made, who made it and how the regulatory conclusion followed from the evidence.

Key Takeaways

1. Potential serious risk to public health is a specific regulatory concept under the EU medicines framework.
2. Article 29 applies to qualifying disagreements arising during MRP/DCP procedures.
3. Not every scientific disagreement constitutes an Article 29 disagreement.
4. A CMS must provide detailed reasons for its position.
5. The assessment should consider evidence, seriousness, plausibility, exposure, alternatives and public-health significance.
6. A safety signal is not automatically a potential serious risk to public health.
7. The concept is not limited to pharmacovigilance issues.
8. CMDh provides an opportunity to resolve the disagreement before Union-level escalation.
9. An Article 29 referral does not itself establish that a medicine is unsafe.
10. The current legislation, Commission guidance and procedure-specific documents should be used for live regulatory decisions.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Articles 28 and 29 provide the legal framework for mutual recognition/decentralised procedures and disagreements based on a potential serious risk to public health.
2. European Commission. Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC (2006/C 133/05). Commission guidance concerning the regulatory concept.
3. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current procedural guidance concerning MRP/DCP disagreements and coordination.
4. European Medicines Agency. Referral procedures for human medicines. Current information concerning Union-level referral procedures.

Regulatory Note

This article is an educational explanation of the potential serious risk to public health concept in the EU medicines regulatory framework. It is not legal advice and does not replace the current consolidated legislation, Commission guidance, CMDh guidance or procedure-specific regulatory documents.

For a live regulatory procedure, the current applicable legal and procedural documents take precedence over this general explanation.

14. From Scientific Concern to Regulatory Qualification

The central discipline in assessing a potential serious risk to public health is to keep the scientific question separate from the procedural consequence. A regulator may identify uncertainty, an unexpected finding or an important difference of interpretation without that issue automatically meeting the Article 29 threshold.

A useful sequence is:

Observation
   ↓
Scientific assessment
   ↓
Potential clinical consequence
   ↓
Public-health significance
   ↓
Regulatory qualification

The last step should follow the evidence rather than precede it. This is particularly important when a concern is being documented for formal regulatory communication.

15. The Role of the Applicant's Response

The applicant's response is part of the evidentiary record. It should address the substance of the concern rather than simply argue that the existing assessment is adequate.

A strong response normally identifies:

• the evidence relied upon;
• limitations of that evidence;
• alternative explanations;
• the clinical interpretation;
• the relevance to the exposed population;
• the effect on benefit-risk balance;
• and any proposed regulatory measures.

Where additional analyses are performed, the methods and assumptions should be sufficiently transparent for the authorities to evaluate them.

The objective is not to produce the most favourable interpretation of the evidence. It is to provide a defensible assessment that allows the authorities to determine whether the concern is substantiated and how it should be addressed.

16. Why Evidence Quality Matters More Than Evidence Volume

A large dossier does not necessarily provide a strong answer to a public-health concern.

Ten weakly informative observations do not necessarily outweigh one well-designed epidemiological study, and a statistically significant finding does not automatically establish clinical or regulatory importance.

The assessment should therefore consider:

• study design;
• internal validity;
• consistency;
• biological plausibility;
• temporality;
• magnitude of association where estimable;
• precision;
• confounding;
• bias;
• and applicability to the relevant population.

For pharmacovigilance evidence, the assessment should also distinguish reporting frequency from incidence and avoid interpreting spontaneous-report counts as direct measures of risk without appropriate context.

17. Seriousness, Severity and Regulatory Significance

The terms serious, severe and significant should not be used interchangeably.

In clinical and pharmacovigilance practice, seriousness has a defined regulatory meaning in relation to outcomes such as death, life-threatening events, hospitalisation and other specified consequences. Severity describes the intensity of a clinical manifestation.

The Article 29 concept of a potential serious risk to public health is a broader regulatory assessment and should not be reduced to the pharmacovigilance definition of a serious adverse event.

A serious adverse event can occur without representing a potential serious risk to public health. Conversely, a public-health concern can arise from the aggregate implications of a risk rather than from one individual case.

18. Population-Level Thinking

The public-health dimension requires consideration beyond the individual patient.

An assessment should ask what could happen if the regulatory concern is correct across the population that may receive the medicine. This requires consideration of exposure, susceptibility, duration of treatment, expected use and the characteristics of the risk.

For example, a rare event may still be important when exposure is extensive and the consequences are catastrophic. Conversely, a frequently reported but clinically minor event may not constitute a potential serious risk to public health.

The conclusion therefore depends on the interaction between probability, severity, exposure and the available evidence rather than on any single attribute.

19. Vulnerable Populations

Particular attention may be necessary where the concern affects a population with limited physiological reserve or increased susceptibility to harm.

Examples can include:

• children;
• older people;
• pregnant patients or fetuses;
• patients with renal or hepatic impairment;
• immunocompromised patients;
• or patients with serious underlying disease.

The relevance of vulnerability should be demonstrated from the evidence and the clinical context. It should not be invoked merely as a rhetorical reason for classifying a concern as serious.

20. Risk Management Does Not Automatically Eliminate the Concern

A proposed warning, contraindication, monitoring recommendation or other risk-minimisation measure may reduce risk, but the adequacy of the measure must itself be assessed.

Questions may include:

• Can the risk be recognised reliably?
• Is the relevant patient or prescriber able to act on the information?
• Is adherence to the measure realistic?
• Can the effectiveness of the measure be evaluated?
• Does residual risk remain clinically important?

A risk-management measure should therefore be evaluated as part of the benefit-risk assessment rather than treated as an automatic solution.

21. The Importance of Proportionality

The regulatory response should be proportionate to the evidence and potential consequence.

Possible regulatory responses can range from clarification of product information to restrictions or other measures available under the applicable legal framework.

The existence of a serious concern does not predetermine which regulatory measure is appropriate. The appropriate response depends on the nature of the evidence, the clinical context, the feasibility of risk control and the applicable legislation.

This is why a regulatory assessment should describe both the concern and the available ways of addressing it.

22. Distinguishing a Data Gap From a Public-Health Risk

A missing piece of information is not automatically a serious public-health risk.

For example, the absence of a long-term study may represent uncertainty. Whether it constitutes a potential serious risk depends on what is already known, what harm is plausible, how the medicine is used and whether the uncertainty could materially affect the benefit-risk assessment.

The same principle applies to incomplete subgroup information, limited exposure data or uncertainty about a rare event.

The assessment should therefore avoid the shortcut:

data gap = serious risk

Instead:

data gap → uncertainty → scientific interpretation → potential consequence → regulatory significance

23. Distinguishing a Signal From a Regulatory Conclusion

Signal management and regulatory decision-making operate at different levels.

A signal is information suggesting a new potentially causal association or a new aspect of a known association that warrants further investigation. The investigation may ultimately confirm, refute or substantially modify the concern.

An Article 29 assessment asks a different question: whether a regulatory position cannot be accepted because of a potential serious risk to public health.

The two concepts can intersect, but neither should be substituted for the other.

24. Benefit-Risk Is a Structured Scientific Judgement

The benefit-risk assessment should identify the relevant benefits and risks and explain how the evidence affects the overall regulatory conclusion.

Relevant considerations can include:

The table is a reasoning aid, not a statutory scoring algorithm.

25. How a Strong Regulatory Argument Is Written

A strong regulatory argument should be explicit about the chain from evidence to conclusion.

For example:

The available evidence indicates X. The principal limitation is Y. Alternative explanation Z has been considered. If the observed association represents a true medicinal-product effect, the expected clinical consequence would be A in population B. The potential exposure is C. The proposed measure D would reduce, but may not eliminate, the risk. On this basis, the concern is considered [regulatory conclusion], subject to the applicable legal assessment.

This is preferable to statements such as "the risk is unacceptable" without explaining why.

26. Handling Conflicting Evidence

Conflicting evidence is common in medicines regulation.

The existence of studies pointing in different directions does not by itself resolve the issue. The evidence should be weighted according to methodological quality, relevance, consistency and the biological and clinical context.

A regulatory assessment should explicitly acknowledge important contradictory evidence rather than selecting only the findings supporting the preferred conclusion.

This is particularly important in a formal disagreement, because the authorities need to understand not only why a concern exists but also why alternative interpretations have been rejected or considered less persuasive.

27. Regulatory Documentation and Traceability

The regulatory file should permit reconstruction of the assessment at the time the decision was made.

A useful evidence table can include:

This structure is especially useful for inspection readiness because it links source evidence to the regulatory conclusion.

28. What Happens After the Threshold Is Accepted?

Once the concern has been established as a qualifying regulatory issue, the procedure moves into the applicable disagreement mechanism.

The Member States attempt to reach agreement through CMDh. The applicant has an opportunity to present its views. If agreement is not reached within the applicable period, the matter proceeds under Article 29(4) to the subsequent Union-level procedure.

The important distinction is that assessment of the threshold precedes the procedural consequence. The procedure should not be used to manufacture evidence for a conclusion that has not been scientifically established.

29. Relationship With Article 29(4)

Article 29(4) is the escalation mechanism when the Member States cannot reach agreement at the coordination-group stage.

The threshold discussed in this article is therefore closely linked to Article 29(4), but the two concepts should not be conflated.

• Potential serious risk to public health describes the substantive regulatory concern.
• Article 29 provides the procedural framework for the disagreement.
• Article 29(4) provides for escalation when the Member States cannot reach agreement under the applicable process.

Keeping these concepts separate makes regulatory records considerably easier to interpret.

30. Practical QPPV Governance

Where a potential serious risk concerns safety, the QPPV should ensure that the pharmacovigilance system remains appropriately connected to the regulatory assessment.

The QPPV should be able to answer:

• What is the safety concern?
• What evidence supports it?
• Is it already known within the safety surveillance system?
• What is the current benefit-risk assessment?
• What regulatory measures are being considered?
• What changes to PV activities may be required?
• What will the final outcome mean for the safety profile and risk-management system?

This does not require the QPPV to own the legal procedure. It requires effective oversight of the pharmacovigilance implications.

31. Practical Regulatory Checklist

Before characterising a concern as a potential serious risk to public health, confirm that the record addresses:

1. The precise regulatory decision in dispute.
2. The evidence supporting the concern.
3. The limitations and uncertainties in that evidence.
4. Alternative explanations.
5. Clinical seriousness and potential consequences.
6. The population potentially exposed.
7. Expected exposure and relevant vulnerability.
8. The potential public-health impact.
9. The benefit-risk implications.
10. Available risk-minimisation or regulatory measures.
11. The adequacy of the proposed product information.
12. The applicable legal and Commission guidance framework.
13. The reasoning supporting the procedural qualification.
14. Traceability to the underlying evidence.

The final regulatory conclusion should be written only after these elements have been considered.

Key Takeaways

1. The potential serious risk to public health concept is a substantive regulatory threshold, not a synonym for scientific disagreement.
2. Evidence must be evaluated in its clinical, epidemiological and public-health context.
3. Seriousness of an individual event is not equivalent to public-health significance.
4. Exposure, vulnerable populations and the magnitude of potential harm are important contextual considerations.
5. A signal, data gap or uncertainty does not automatically satisfy the threshold.
6. Alternative explanations and contradictory evidence should be addressed explicitly.
7. Risk-minimisation measures must be assessed for adequacy rather than assumed to eliminate the concern.
8. The applicant's response forms part of the evidentiary record and should address the scientific substance of the concern.
9. The potential serious risk assessment and Article 29 procedural escalation are related but distinct concepts.
10. Where safety is involved, the QPPV should maintain appropriate pharmacovigilance oversight while preserving clear ownership of the regulatory procedure.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. In particular Articles 28–29 and the provisions governing the subsequent Union procedure.
2. European Commission. Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC (2006/C 133/05). Primary Commission guidance specifically addressing the concept discussed in this article.
3. CMDh. Current guidance concerning Mutual Recognition and Decentralised Procedures. Current procedural guidance for MRP/DCP and management of disagreements.
4. European Medicines Agency. Referral procedures for human medicines. Current information concerning Union referral mechanisms and their regulatory context.
5. European Medicines Agency. Good Pharmacovigilance Practices. Current guidance relevant to signal management, safety evaluation and risk-management activities where pharmacovigilance evidence contributes to a regulatory assessment.

Regulatory Note

This article is an educational explanation of the potential serious risk to public health concept in the context of MRP/DCP disagreements. It does not constitute legal advice and does not replace the current consolidated legislation, applicable Commission guidance, CMDh guidance, EMA guidance or procedure-specific regulatory documents.

The assessment should not be reduced to an internally created numerical score or checklist. The applicable legal definition, Commission guidance and the evidence available in the individual procedure must be considered together.

The article deliberately distinguishes the substantive assessment of the potential serious risk from the procedural consequences under Article 29. The related article What Happens When Member States Disagree During an MRP or DCP? addresses the procedural pathway in greater detail.

Where a live regulatory procedure is being assessed, the current legislation, formal regulatory communications, procedure-specific documents and legally operative decisions take precedence over this general educational explanation.

32. Final Regulatory Interpretation

The concept of a potential serious risk to public health should be applied as a legal and scientific threshold, not as a general expression of regulatory concern.

The assessment should connect the evidence to the potential clinical and public-health consequence and explain why the concern meets the applicable framework. It should also acknowledge uncertainty, contradictory evidence and the potential effectiveness of risk-minimisation measures.

The most defensible regulatory record is therefore one in which another appropriately qualified reviewer can reconstruct the reasoning without having to infer the conclusion from the outcome.

33. Relationship to the MRP/DCP Lifecycle

The concept is particularly important because it forms part of the boundary between ordinary MRP/DCP coordination and formal disagreement procedures.

It should therefore be understood together with the articles on:

• the Mutual Recognition Procedure;
• the Decentralised Procedure;
• RMS and CMS interaction;
• disagreement between Member States during MRP/DCP; and
• the Article 29(4) escalation mechanism.

Taken together, these articles describe a progression from coordinated national assessment to formal Union-level intervention where the legal conditions require it.

34. Practical Review Questions

When reviewing an actual case, a regulatory professional should be able to answer the following questions from the evidence file:

1. What precisely is the disputed scientific or regulatory issue?
2. What evidence supports the concern?
3. How reliable and relevant is that evidence?
4. What alternative explanations have been considered?
5. What is the potential clinical consequence?
6. Which patients could be affected?
7. What level of exposure is relevant?
8. What is the potential population-level impact?
9. What benefits does the medicine provide in the relevant population?
10. Can the risk be adequately managed?
11. What uncertainty remains?
12. Why does the issue satisfy, or fail to satisfy, the applicable regulatory concept?
13. What procedural consequence follows from that conclusion?

These questions are deliberately analytical rather than numerical. There is no generic scoring formula that can replace the applicable legal and scientific assessment.

Key Takeaways

1. Potential serious risk to public health is a specific regulatory concept within the MRP/DCP disagreement framework.
2. The assessment requires both scientific evidence and consideration of public-health consequences.
3. Seriousness of an individual adverse event should not be confused with the regulatory public-health threshold.
4. Exposure, affected population, clinical consequence, uncertainty and available risk controls all influence the assessment.
5. Signals and data gaps can contribute to the evidence but do not automatically establish the threshold.
6. Conflicting evidence should be acknowledged and weighed rather than selectively presented.
7. Risk-minimisation measures should be assessed for their actual ability to control the relevant risk.
8. The applicant's response is part of the regulatory evidentiary record.
9. The substantive threshold and the Article 29 procedural mechanism are distinct concepts.
10. The final regulatory conclusion should be traceable to the evidence and applicable legal framework.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Particularly Articles 28–29 and the provisions governing the subsequent Union procedure. This is the primary legal framework for the MRP/DCP disagreement mechanism.
2. European Commission. Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC (2006/C 133/05). Commission guidance specifically addressing the concept discussed in this article.
3. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current procedural guidance on MRP and DCP. Current material concerning assessment, coordination and disagreement procedures.
4. European Medicines Agency. Referral procedures for human medicines. Current explanatory material concerning Union referral mechanisms.
5. European Medicines Agency. Good Pharmacovigilance Practices (GVP). Current guidance relevant to pharmacovigilance evidence, safety evaluation, signal management and risk-management activities.

Regulatory Note

This article is an educational explanation of the potential serious risk to public health concept in the context of mutual recognition and decentralised procedures for human medicinal products. It is not legal advice and does not replace the current consolidated legislation, Commission guidance, CMDh guidance, EMA guidance or procedure-specific regulatory documents.

The concept should not be converted into an internally created numerical threshold. The applicable legislation and Commission guidance should be considered together with the evidence and circumstances of the individual procedure.

The article deliberately focuses on the assessment of the substantive concept. The procedural consequences of a Member State disagreement are addressed separately in What Happens When Member States Disagree During an MRP or DCP?

Regulatory terminology and guidance can change. For a live regulatory matter, the current legislation, formal regulatory communications, procedure-specific documents and legally operative decisions take precedence over this general educational article.